Scholarlink

<p>Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) provides cardiopulmonary support during the critical care. Despite its exponential use over last few decades, clinical studies suggest that it does not improve infarct size and mortality in patients suffering from cardiogenic shock after the acute myocardial infarction (AMI). The effect of hyperoxygenated blood under high pressure on the poor outcomes associated with VA-ECMO have not been tested. In this study we tested the hypothesis whether normoxemic oxygenation of blood during provides protection against VA-ECMO associated cardiac damage using&#xa0;a&#xa0;swine model of AMI. Our results indicate that normoxemic VA-ECMO (PaO2 &lt; 200&#xa0;mmHg), reduces infarct size, activates pro-survival RISK pathway and furthermore preserves mitochondrial structure and function as compared to hyperoxygenated VA-ECMO (PaO2 &gt; 200&#xa0;mmHg) in ischemia–reperfusion injury. In absence of conclusive clinical trials testing&#xa0;the effect of VA-ECMO blood oxygenation on the patients’ outcomes, our findings provide new mechanistic insight into the myocardial effects of VA-ECMO.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Normoxemic Extracorporeal Membrane Oxygenation Reduces Infarct Size and Preserves Mitochondrial Integrity in Preclinical Models of Acute Myocardial Infarction

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月21日

查看全文
  • Shreyas Bhave,
  • Lija Swain,
  • Lara Reyelt,
  • Xiaoying Qiao,
  • Tejasvi Aryaputra,
  • Kay Everett,
  • Kevin John,
  • Isabella Berry,
  • Arik Stolyaranov,
  • Elena Mahmoudi,
  • Michael Chin,
  • Navin K. Kapur

摘要

Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) provides cardiopulmonary support during the critical care. Despite its exponential use over last few decades, clinical studies suggest that it does not improve infarct size and mortality in patients suffering from cardiogenic shock after the acute myocardial infarction (AMI). The effect of hyperoxygenated blood under high pressure on the poor outcomes associated with VA-ECMO have not been tested. In this study we tested the hypothesis whether normoxemic oxygenation of blood during provides protection against VA-ECMO associated cardiac damage using a swine model of AMI. Our results indicate that normoxemic VA-ECMO (PaO2 < 200 mmHg), reduces infarct size, activates pro-survival RISK pathway and furthermore preserves mitochondrial structure and function as compared to hyperoxygenated VA-ECMO (PaO2 > 200 mmHg) in ischemia–reperfusion injury. In absence of conclusive clinical trials testing the effect of VA-ECMO blood oxygenation on the patients’ outcomes, our findings provide new mechanistic insight into the myocardial effects of VA-ECMO.

Graphical Abstract